Literature DB >> 21119336

An algorithm for use of prasugrel (effient) in patients undergoing cardiac catheterization and percutaneous coronary intervention.

Julio Marchini1, David Morrow, Frederic Resnic, Andre Manica, James Kirshenbaum, Christopher Cannon, Kevin Croce.   

Abstract

An algorithm for use of Prasugrel (Effient) in patients undergoing cardiac catheterization and percutaneous coronary intervention at the Brigham and Women's Hospital is presented. Our algorithm, which is in the process of being implemented, is consistent with published and generally accepted standards of care and is based on data from the pivotal Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction (TRITON-TIMI) 38, which compared clopidogrel with prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention. Areas of focus include analysis of the benefit of prasugrel over clopidogrel in acute coronary syndrome patients and appropriate selection of patients for prasugrel treatment.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21119336      PMCID： PMC3039920          DOI： 10.1097/HPC.0b013e3181fe9817

Source DB:  PubMed          Journal:  Crit Pathw Cardiol        ISSN： 1535-2811


  28 in total

1.  Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study.

Authors:  Giuseppe Patti; Giuseppe Colonna; Vincenzo Pasceri; Leonardo Lassandro Pepe; Antonio Montinaro; Germano Di Sciascio
Journal:  Circulation       Date:  2005-03-06       Impact factor: 29.690

2.  High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome.

Authors:  T Cuisset; C Frere; J Quilici; F Barbou; P E Morange; T Hovasse; J-L Bonnet; M-C Alessi
Journal:  J Thromb Haemost       Date:  2005-12-22       Impact factor: 5.824

3.  Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.

Authors:  Thomas Cuisset; Corinne Frere; Jacques Quilici; Pierre-Emmanuel Morange; Lyassine Nait-Saidi; Joseph Carvajal; Agnès Lehmann; Marc Lambert; Jean-Louis Bonnet; Marie-Christine Alessi
Journal:  J Am Coll Cardiol       Date:  2006-09-12       Impact factor: 24.094

4.  Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study.

Authors:  Marc S Sabatine; Christopher P Cannon; C Michael Gibson; Jose L López-Sendón; Gilles Montalescot; Pierre Theroux; Basil S Lewis; Sabina A Murphy; Carolyn H McCabe; Eugene Braunwald
Journal:  JAMA       Date:  2005-09-04       Impact factor: 56.272

5.  Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.

Authors:  Shamir R Mehta; Jean-Francois Tanguay; John W Eikelboom; Sanjit S Jolly; Campbell D Joyner; Christopher B Granger; David P Faxon; Hans-Jurgen Rupprecht; Andrzej Budaj; Alvaro Avezum; Petr Widimsky; Philippe Gabriel Steg; Jean-Pierre Bassand; Gilles Montalescot; Carlos Macaya; Giuseppe Di Pasquale; Kari Niemela; Andrew E Ajani; Harvey D White; Susan Chrolavicius; Peggy Gao; Keith A A Fox; Salim Yusuf
Journal:  Lancet       Date:  2010-10-09       Impact factor: 79.321

Review 6.  Clopidogrel treatment surrounding percutaneous coronary intervention: when should it be started and stopped?

Authors:  Alanna Coolong; Laura Mauri
Journal:  Curr Cardiol Rep       Date:  2006-07       Impact factor: 2.931

7.  Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.

Authors:  S R Mehta; S Yusuf; R J Peters; M E Bertrand; B S Lewis; M K Natarajan; K Malmberg; H Rupprecht; F Zhao; S Chrolavicius; I Copland; K A Fox
Journal:  Lancet       Date:  2001-08-18       Impact factor: 79.321

8.  Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis.

Authors:  Piergiovanni Buonamici; Rossella Marcucci; Angela Migliorini; Gian Franco Gensini; Alberto Santini; Rita Paniccia; Guia Moschi; Anna Maria Gori; Rosanna Abbate; David Antoniucci
Journal:  J Am Coll Cardiol       Date:  2007-06-04       Impact factor: 24.094

9.  Prasugrel versus clopidogrel in patients with acute coronary syndromes.

Authors:  Stephen D Wiviott; Eugene Braunwald; Carolyn H McCabe; Gilles Montalescot; Witold Ruzyllo; Shmuel Gottlieb; Franz-Joseph Neumann; Diego Ardissino; Stefano De Servi; Sabina A Murphy; Jeffrey Riesmeyer; Govinda Weerakkody; C Michael Gibson; Elliott M Antman
Journal:  N Engl J Med       Date:  2007-11-04       Impact factor: 91.245

10.  Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.

Authors:  J T Brandt; S L Close; S J Iturria; C D Payne; N A Farid; C S Ernest; D R Lachno; D Salazar; K J Winters
Journal:  J Thromb Haemost       Date:  2007-09-26       Impact factor: 5.824
View more
  4 in total

1.  Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome. An analysis from the 'real world'.

Authors:  Manuel Almendro-Delia; Emilia Blanco Ponce; Rocío Gomez-Domínguez; Carlos Gonzalez-Matos; Manuel Lobo-Gonzalez; Auxiliadora Caballero-Garcia; Rafael Hidalgo-Urbano; Maria Jose Cruz-Fernandez; Juan C Garcia-Rubira
Journal:  J Thromb Thrombolysis       Date:  2015-05       Impact factor: 2.300

2.  Stent thrombosis: understanding and managing a critical problem.

Authors:  Julio F Marchini; Andre Manica; Kevin Croce
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-02

Review 3.  Pharmacotherapy in the cardiac catheterization laboratory: evolution and recent developments.

Authors:  Guramrinder S Thind; Raunak Parida; Nishant Gupta
Journal:  Ther Clin Risk Manag       Date:  2014-10-21       Impact factor: 2.423

4.  No Pharmacokinetic Drug-Drug Interaction Between Prasugrel and Vorapaxar Following Multiple-Dose Administration in Healthy Volunteers.

Authors:  Matt S Anderson; Teddy Kosoglou; Paul Statkevich; Jing Li; Jennifer Rotonda; Alan G Meehan; David L Cutler
Journal:  Clin Pharmacol Drug Dev       Date:  2017-04-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.